AI MARKET SCANNING

Supernus Pharmaceuticals, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Drug Manufacturers – Specialty & Generic
AVG HISTORICAL GAP +0.68%
MAX GAP RECORD -21.58%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $SUPN
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 03, 2026 Earnings Release 2026-08-03 (UNDETERMINED)
+0.00%
May 05, 2026 Earnings Release 2026-05-05 (AFTER CLOSE)
+3.01%
Feb 24, 2026 Earnings Release 2026-02-24 (AFTER CLOSE)
+6.00%
Nov 04, 2025 Earnings Release 2025-11-04 (AFTER CLOSE)
-21.58%
Aug 05, 2025 Earnings Release 2025-08-05 (AFTER CLOSE)
+4.32%
May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE)
-7.37%
Feb 25, 2025 Earnings Release 2025-02-25 (AFTER CLOSE)
+2.38%
Nov 04, 2024 Earnings Release 2024-11-04 (AFTER CLOSE)
+13.46%

VOLATILITY & GAP BIAS

AVG GAP MOVE 6.2%
Bullish Gaps (8)
Bearish Gaps (5)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $SUPN

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗